Stryker to acquire Inari Medical for $4.9B

January 07, 2025

Lauren Dubinsky  

Stryker plans to acquire Inari Medical in a deal valued at $4.9 billion and designed to strength its position in the peripheral vascular market.

The deal, announced Monday and approved by both companies’ boards, is expected to close by the end of the first quarter. Stryker will purchase Inari’s common stock for $80 per share.

Inari Medical’s product portfolio includes medical devices that treat pulmonary embolism, deep vein thrombosis, in-stent thrombosis and arteriovenous fistula. Stryker said the products are “highly complementary” to its neurovascular business.

To read full article, click here